 Gene-editing concern LogicBio Therapeutics, Inc. has lost 90 million of market cap since an IND clinical hold was placed on its LB-001 candidate in February 2020. The hold was lifted in August 2020 with its first patient expected to be dosed in early 2021 in a Phase 12 trial. 